Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2022.5409
Abstract: Importance Increased survival with immune checkpoint inhibitors has been reported for patients with obesity vs a normal body mass index (BMI). However, the association of obesity with the safety of immune checkpoint inhibitors warrants study.… read more here.
Keywords: nivolumab plus; patients obesity; plus ipilimumab; grade iraes ... See more keywords
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
Sign Up to like & getrecommendations! Published in 2017 at "Investigational New Drugs"
DOI: 10.1007/s10637-017-0534-0
Abstract: SummaryBackground Immunotherapy is emerging as the cornerstone for treatment of patients with advanced cancer, but significant toxicity (immune-related adverse events [irAEs]) associated with unbridled T cell activity remains a concern. Patients and methods A retrospective… read more here.
Keywords: incidence; immune; grade iraes; treatment ... See more keywords
Late immune-related adverse events with immune checkpoint inhibitors.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.2635
Abstract: 2635 Background: Immune Checkpoint Inhibitors (ICIs) are associated with unique immune-related adverse events (irAEs). IrAEs can occur at any timepoint of ICI treatment. Late irAEs are not well reported in the literature. Herein, we attempt… read more here.
Keywords: immune checkpoint; iraes; treatment; grade iraes ... See more keywords
Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14163878
Abstract: Simple Summary Immune checkpoint inhibitors (ICIs) recently became a standard treatment for advanced non-small-cell lung cancers (NSCLCs). Immune-related adverse events (irAEs) could occur in 10 to 80% of treated patients but were reported to associate… read more here.
Keywords: cell; high grade; iraes; grade iraes ... See more keywords